Thursday, 2 April 2009

Med BioGene Featured in Top Industry Publication

Basic shares: 40 million
Fully diluted: 58 million

On March 24, 2008 featured Med BioGene in an article titled, “Med BioGene Will Launch LungExpress Dx in H2, Establish US Office, CEO Says.”
Highlights from the article include:

- According to CEO Erinn Broshko, Med BioGene is on track to launch its LungExpress assay in the second half of this year and will likely open a US office to support the test, which will initially be offered in a Clinical Laboratory Improvement Amendment (CLIA) -compliant partner lab.

- …LungExpress Dx has the potential to increase the five-year survival rate by up to 33 percent while decreasing health care costs significantly.

- The main reason for the expected cost savings is a decrease in treatment failure and terminal care costs associated with cancer recurrence, which in the United States can range between $150,000 to $500,000 per patient, the firm claims.

- In terms of other gene-expression signatures for Non-small Cell Lunch Cancer (CSLC), MBI is the only group with a signature predictive of adjuvant chemotherapy benefit and prognostic for survival.

To read the full article, please click here

GenomeWeb ( ) is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research.

GenomeWeb's editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics. Our expert editors report and write with precision and clarity.

GenomeWeb users can be found in major scientific organizations around the world, including biopharmaceutical companies, important research universities, biomedical institutes, and government laboratories. Our advertisers include leading suppliers of research tools, analytical instruments, and information technology.